Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from McGill University suggests.
The positive outcome from the clinical phase IIa CHIC study and the preclinical studies have now convinced NeuroVive to proceed into the next stage of clinical development.